Shorter TB Regimen Misses the Mark
But researchers still see potential for high-dose rifampicin-based treatment strategy
Source: medpagetoday.com
Page 2 - Randomised Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomised Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomised Trial Today - Breaking & Trending Today
Offline: FRENCH-ARRIVE—elles accusent
The accusation is direct and unflinching. The FRENCH-ARRIVE trial “obeys a pseudo-scientific rational logic” that is “a denial of what childbirth and motherhood mean to women”. Claudine Schalck and Raymonde Gagnon are both registered midwives. Their book, When Inducing Labor Compromises a Woman's Motherhood (L’Harmattan, 2022), is one of the most remarkable denunciations of an ongoing research study ever published. It is also a sustained critique of the contemporary approach to obstetric care in many western nations today.
Source: thelancet.com
Prof Aldous clarifies the outcome of the colon cancer study as positive
Professor Colleen Aldous dissects the NEJM colon cancer study and highlights the error of interpretation by the global mainstream media.
Source: biznews.com
Significant University research funded by Health Research Council
The grants announced on 30 June include:Professor Alistair Gunn, Faculty of Medical and Health SciencesPathogenesis, detection and treatment of perinatal brain injury60 months $4,999,982.55Perinatal brain injury is the single greatest cause of disabi
Source: indiaeducationdiary.in
ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for childr
Search jobs 13-Jan-2021 ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay , - Dolutegravir is the first integrase inhibitor available as a dispersible tablet for children weighing at least 3kg and from four weeks of age - The authorisation is an importa...
Source: pharmiweb.com